Quarterly report pursuant to Section 13 or 15(d)

Restatement Of Previously Issued Financial Statements - Schedule of Unaudited Consolidated Interim Financial Statements (Details)

v3.22.4
Restatement Of Previously Issued Financial Statements - Schedule of Unaudited Consolidated Interim Financial Statements (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Balance Sheet                    
Warrant Liabilities $ 215,705           $ 215,705      
Total current liabilities and long term liabilities 2,671,998           2,671,998   $ 2,145,996  
Additional paid-in capital 52,222,752           52,222,752   37,618,438  
Accumulated deficit (40,061,534)           (40,061,534)   (28,437,993)  
Total stockholders' equity 12,110,667 $ 6,662,088 $ 9,013,670 $ 10,230,886 $ (3,688,535) $ (2,581,292) 12,110,667 $ 10,230,886 9,181,203 $ (1,616,300)
Statement of Operations                    
Ratchet share expense 1,099,360           1,099,360      
Loss from operations (5,095,586)     (2,233,247)     (11,981,188) (4,787,216)    
Change in fair value of warrant liability 128,030     (100,780)     128,030 (1,546,280)    
Other income (expense) net 191,773     (2,970,321)     357,647 (4,898,261)    
Net loss (4,903,813) (3,305,883) (3,413,845) (5,203,568) (2,956,324) (1,525,585) (11,623,541) (9,685,477)    
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ (4,903,813)     $ (5,196,438)     $ (12,074,119) $ (9,611,146)    
Net loss per share basic $ (0.48)     $ (1.02)     $ (1.39) $ (2.06)    
Net loss per share diluted $ (0.48)     $ (1.02)     $ (1.39) $ (2.06)    
Statement of Changes in Condensed Consolidated Statement of Comprehensive Loss                    
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ (4,903,813)     $ (5,196,438)     $ (12,074,119) $ (9,611,146)    
Comprehensive loss to MAIA Biotechnology, Inc. shareholders (4,951,314)     (5,196,438)     (12,125,765) (9,611,146)    
Statement Of Stockholders Equity [Abstract]                    
Net loss (4,903,813) (3,305,883) (3,413,845) (5,203,568) (2,956,324) (1,525,585) (11,623,541) (9,685,477)    
Total equity 12,110,667 6,662,088 9,013,670 10,230,886 (3,688,535) (2,581,292) 12,110,667 10,230,886 9,181,203 (1,616,300)
Statement of Cash Flows                    
Net loss, including noncontrolling interests (4,903,813) (3,305,883) (3,413,845) (5,203,568) (2,956,324) (1,525,585) (11,623,541) (9,685,477)    
Change in fair value of warrant liability (128,030)     100,780     (128,030) 1,546,280    
Issuance of ratchet shares             1,099,360      
Net cash used in operating activities             (9,146,390) (2,515,658)    
Additional Paid-In Capital                    
Balance Sheet                    
Total stockholders' equity 52,222,752 41,823,112 40,862,993 36,095,420 14,773,088 13,041,091 52,222,752 36,095,420 37,618,438 12,599,585
Statement Of Stockholders Equity [Abstract]                    
Total equity 52,222,752 41,823,112 40,862,993 36,095,420 14,773,088 13,041,091 52,222,752 36,095,420 37,618,438 12,599,585
Accumulated Deficit                    
Balance Sheet                    
Total stockholders' equity (40,061,534) (35,157,721) (31,851,838) (25,545,259) (20,348,821) (17,422,173) (40,061,534) (25,545,259) (28,437,993) (15,934,113)
Statement of Operations                    
Net loss (4,903,813) (3,305,883) (3,413,845) (5,196,438) (2,926,648) (1,488,060)        
Statement Of Stockholders Equity [Abstract]                    
Net loss (4,903,813) (3,305,883) (3,413,845) (5,196,438) (2,926,648) (1,488,060)        
Total equity (40,061,534) (35,157,721) (31,851,838) (25,545,259) (20,348,821) (17,422,173) (40,061,534) $ (25,545,259) $ (28,437,993) $ (15,934,113)
Statement of Cash Flows                    
Net loss, including noncontrolling interests (4,903,813) $ (3,305,883) $ (3,413,845) $ (5,196,438) $ (2,926,648) $ (1,488,060)        
As Previously Reported                    
Balance Sheet                    
Total current liabilities and long term liabilities 2,456,293           2,456,293      
Additional paid-in capital 51,467,127           51,467,127      
Accumulated deficit (39,090,204)           (39,090,204)      
Total stockholders' equity 12,326,372           12,326,372      
Statement of Operations                    
Loss from operations (3,996,226)           (10,881,828)      
Other income (expense) net 63,743           229,617      
Net loss (3,932,483)           (10,652,211)      
Deemed dividend on ratchet shares (1,099,360)           (1,099,360)      
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ (5,031,843)           $ (12,202,149)      
Net loss per share basic $ (0.49)           $ (1.40)      
Net loss per share diluted $ (0.49)           $ (1.40)      
Statement of Changes in Condensed Consolidated Statement of Comprehensive Loss                    
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ (5,031,843)           $ (12,202,149)      
Comprehensive loss to MAIA Biotechnology, Inc. shareholders (5,079,344)           (12,253,795)      
Statement Of Stockholders Equity [Abstract]                    
Deemed dividend for ratchet shares (1,099,360)                  
Net loss (3,932,483)           (10,652,211)      
Total equity 12,326,372           12,326,372      
Statement of Cash Flows                    
Net loss, including noncontrolling interests (3,932,483)           (10,652,211)      
Net cash used in operating activities             (9,146,390)      
As Previously Reported | Additional Paid-In Capital                    
Balance Sheet                    
Total stockholders' equity 51,467,127           51,467,127      
Statement Of Stockholders Equity [Abstract]                    
Total equity 51,467,127           51,467,127      
As Previously Reported | Accumulated Deficit                    
Balance Sheet                    
Total stockholders' equity (39,090,204)           (39,090,204)      
Statement Of Stockholders Equity [Abstract]                    
Total equity (39,090,204)           (39,090,204)      
Adjustment                    
Balance Sheet                    
Warrant Liabilities 215,705           215,705      
Total current liabilities and long term liabilities 215,705           215,705      
Additional paid-in capital 755,625           755,625      
Accumulated deficit (971,330)           (971,330)      
Total stockholders' equity (215,705)           (215,705)      
Statement of Operations                    
Ratchet share expense 1,099,360           1,099,360      
Loss from operations (1,099,360)           (1,099,360)      
Change in fair value of warrant liability 128,030           128,030      
Other income (expense) net 128,030           128,030      
Net loss (971,330)           (971,330)      
Deemed dividend on ratchet shares 1,099,360           1,099,360      
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ 128,030           $ 128,030      
Net loss per share basic $ 0.01           $ 0.01      
Net loss per share diluted $ 0.01           $ 0.01      
Statement of Changes in Condensed Consolidated Statement of Comprehensive Loss                    
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ 128,030           $ 128,030      
Comprehensive loss to MAIA Biotechnology, Inc. shareholders 128,030           128,030      
Statement Of Stockholders Equity [Abstract]                    
Deemed dividend for ratchet shares 1,099,360                  
Net loss (971,330)           (971,330)      
Total equity (215,705)           (215,705)      
Statement of Cash Flows                    
Net loss, including noncontrolling interests (971,330)           (971,330)      
Change in fair value of warrant liability (128,030)           (128,030)      
Issuance of ratchet shares             1,099,360      
Net cash used in operating activities             0      
Adjustment | Additional Paid-In Capital                    
Balance Sheet                    
Total stockholders' equity 755,625           755,625      
Statement Of Stockholders Equity [Abstract]                    
Total equity 755,625           755,625      
Adjustment | Accumulated Deficit                    
Balance Sheet                    
Total stockholders' equity (971,330)           (971,330)      
Statement Of Stockholders Equity [Abstract]                    
Total equity $ (971,330)           $ (971,330)